CRISPR/Cas9-mediated induction of relapse-specific NT5C2 and PRPS1 mutations confers thiopurine resistance as a relapsed lymphoid leukemia model

Thao Thu Thi Nguyen; Yoichi Tanaka; Masashi Sanada; Masumi Hosaka; Minori Tamai; Keiko Kagami; Chiaki Komatsu; Shinpei Somazu; Daisuke Harama; Shin Kasai; Atsushi Watanabe; Koushi Akahane; Kumiko Goi; Takeshi Inukai

doi:10.1124/molpharm.122.000546

OtherArticle

**CRISPR/Cas9-mediated induction of relapse-specific NT5C2 and PRPS1 mutations confers thiopurine resistance as a relapsed lymphoid leukemia model**

Thao Thu Thi Nguyen, Yoichi Tanaka, Masashi Sanada, Masumi Hosaka, Minori Tamai, Keiko Kagami, Chiaki Komatsu, Shinpei Somazu, Daisuke Harama, Shin Kasai, Atsushi Watanabe, Koushi Akahane, Kumiko Goi and Takeshi Inukai

Molecular Pharmacology January 20, 2023, MOLPHARM-AR-2022-000546; DOI: https://doi.org/10.1124/molpharm.122.000546

Thao Thu Thi Nguyen

1Pediatrics, University of Yamanashi, Japan

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
ORCID record for Thao Thu Thi Nguyen

Yoichi Tanaka

2Division of Medicinal Safety Science, National Institute of Health Sciences, Japan

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
ORCID record for Yoichi Tanaka

Masashi Sanada

3Advanced Diagnostic Research Department, Clinical Research Center, National Hospital Organization, Nagoya Medical Center, Japan

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Masumi Hosaka

4Advanced Diagnostic Research Department, Clinical Research Center, National Hospital Organization, National Hospital Organization, Nagoya Medical Center, Japan

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Minori Tamai

1Pediatrics, University of Yamanashi, Japan

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
ORCID record for Minori Tamai

Keiko Kagami

1Pediatrics, University of Yamanashi, Japan

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Chiaki Komatsu

1Pediatrics, University of Yamanashi, Japan

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Shinpei Somazu

1Pediatrics, University of Yamanashi, Japan

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
ORCID record for Shinpei Somazu

Daisuke Harama

1Pediatrics, University of Yamanashi, Japan

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Shin Kasai

1Pediatrics, University of Yamanashi, Japan

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Atsushi Watanabe

1Pediatrics, University of Yamanashi, Japan

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
ORCID record for Atsushi Watanabe

Koushi Akahane

1Pediatrics, University of Yamanashi, Japan

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Kumiko Goi

1Pediatrics, University of Yamanashi, Japan

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Takeshi Inukai

5University of Yamanashi, Japan

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
For correspondence: tinukai@yamanashi.ac.jp

Article
Figures & Data
Info & Metrics
eLetters
PDF + SI
PDF

Article Information

MOLPHARM-AR-2022-000546

DOI

https://doi.org/10.1124/molpharm.122.000546

PubMed

36669880

Published By

American Society for Pharmacology and Experimental Therapeutics

Print ISSN

0026-895X

Online ISSN

1521-0111

History

Published online January 20, 2023.

Author Information

Thao Thu Thi Nguyen1,
Yoichi Tanaka2,
Masashi Sanada3,
Masumi Hosaka4,
Minori Tamai1,
Keiko Kagami1,
Chiaki Komatsu1,
Shinpei Somazu1,
Daisuke Harama1,
Shin Kasai1,
Atsushi Watanabe1,
Koushi Akahane1,
Kumiko Goi1, and
Takeshi Inukai5,*

¹Pediatrics, University of Yamanashi, Japan
²Division of Medicinal Safety Science, National Institute of Health Sciences, Japan
³Advanced Diagnostic Research Department, Clinical Research Center, National Hospital Organization, Nagoya Medical Center, Japan
⁴Advanced Diagnostic Research Department, Clinical Research Center, National Hospital Organization, National Hospital Organization, Nagoya Medical Center, Japan
⁵University of Yamanashi, Japan

↵* Corresponding Author:
Takeshi Inukai, University of Yamanashi, 1110 Shimokatou, Chuo, 409-3896, Japan. E-mail: tinukai{at}yamanashi.ac.jp

Statistics from Altmetric.com

Article usage

Article usage: January 2023 to February 2023

	Abstract	Full	Pdf
Jan 2023	230	0	64
Feb 2023	10	0	4

PreviousNext

In this issue

Molecular Pharmacology

Vol. 103, Issue 2

1 Feb 2023

Table of Contents
Table of Contents (PDF)
About the Cover
Index by author
Editorial Board (PDF)
Front Matter (PDF)

Download PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following CRISPR/Cas9-mediated induction of relapse-specific NT5C2 and PRPS1 mutations confers thiopurine resistance as a relapsed lymphoid leukemia model

Message Subject (Your Name) has forwarded a page to you from Molecular Pharmacology

Message Body (Your Name) thought you would be interested in this article in Molecular Pharmacology.

Your Personal Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Citation Tools

OtherArticle